Cargando…

CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain

Advanced central nervous system (CNS) lymphoma is an exclusion criterion for most chimeric antigen receptor (CAR) T-cell studies due to the associated levels of neurotoxicity. In this study, we described five patients with chemorefractory B-cell CNS lymphoma who received CAR19 and CAR22 T-cell “Cock...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tongjuan, Zhao, Lei, Zhang, Yuanyuan, Xiao, Yi, Wang, Di, Huang, Liang, Ma, Liya, Chen, Liting, Liu, Songya, Long, Xiaolu, Meng, Fankai, Zhu, Xiaojian, Wei, Jia, Xu, Bin, Zhou, Jianfeng, Zhou, Xiaoxi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438944/ https://www.ncbi.nlm.nih.gov/pubmed/32903866 http://dx.doi.org/10.3389/fonc.2020.01306

Ejemplares similares

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
por: Li, Tongjuan, et al.
Publicado: (2019)

Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia
por: Zhou, Lanlan, et al.
Publicado: (2022)

Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy
por: Li, Tongjuan, et al.
Publicado: (2020)

Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
por: Wei, Jia, et al.
Publicado: (2019)

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma
por: Wu, Jiaying, et al.
Publicado: (2021)

Clinical characteristics of hematological patients concomitant with COVID‐19
por: Zhou, Xiaoxi, et al.
Publicado: (2020)

TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy
por: Chen, Liting, et al.
Publicado: (2021)

Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT
por: Wei, Jia, et al.
Publicado: (2022)

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
por: Cheng, Jiali, et al.
Publicado: (2019)

CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
por: Chen, Liting, et al.
Publicado: (2020)

Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report
por: Liu, Wanying, et al.
Publicado: (2022)

Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy
por: Luo, Hui, et al.
Publicado: (2019)

CAR-Based Approaches to Cutaneous T-Cell Lymphoma
por: Scarfò, Irene, et al.
Publicado: (2019)

CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report
por: Chen, Liting, et al.
Publicado: (2022)

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
por: Zhang, Ying, et al.
Publicado: (2021)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
por: Fang, Penny Q., et al.
Publicado: (2021)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy
por: Jin, Jin, et al.
Publicado: (2023)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

Identification of methylation signatures associated with CAR T cell in B-cell acute lymphoblastic leukemia and non-hodgkin’s lymphoma
por: Song, Jiwei, et al.
Publicado: (2022)

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma
por: Zundler, Sebastian, et al.
Publicado: (2023)

Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?
por: Goldsmith, Scott R., et al.
Publicado: (2020)

SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity
por: Wei, Jia, et al.
Publicado: (2020)

NEK2 Promotes Cell Proliferation and Glycolysis by Regulating PKM2 Abundance via Phosphorylation in Diffuse Large B-Cell Lymphoma
por: Zhou, Lingna, et al.
Publicado: (2021)

Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells
por: Di, Shengmeng, et al.
Publicado: (2019)

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy
por: Liu, Yuanyuan, et al.
Publicado: (2022)

Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy
por: Vercellino, Laetitia, et al.
Publicado: (2021)

CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences
por: Vitale, Candida, et al.
Publicado: (2020)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Extranodal NK-/T-cell lymphoma, nasal type: what advances have been made in the last decade?
por: Costa, Renata de Oliveira, et al.
Publicado: (2023)

Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia
por: Tang, Ling, et al.
Publicado: (2023)

Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS
por: Zhang, Man, et al.
Publicado: (2023)

A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy
por: Mu, Wei, et al.
Publicado: (2022)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

CAR T Cell Therapy for Pediatric Brain Tumors
por: Patterson, John D., et al.
Publicado: (2020)

Strategies for Dodging the Obstacles in CAR T Cell Therapy
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8pcnhdgbrdda0fkgpip2ob1n33